Skip to content
10-K

Annual Report

ATYR PHARMA, INC. ATYR

0001339970-26-000008

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 98.05M sh
Shares Diluted FY 2025 · Dec 31, 2025 92.99M sh
Shares Diluted FY 2025 · Dec 31, 2024 74.26M sh
Shares Diluted FY 2025 · Dec 31, 2023 53.61M sh
Capex FY 2025 · Dec 31, 2025 $77K
Capex FY 2025 · Dec 31, 2024 $65K
Capex FY 2025 · Dec 31, 2023 $4.22M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$61.99M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$69.12M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$33.22M
Cash And Equivalents FY 2025 · Dec 31, 2025 $10.74M
Cash And Equivalents FY 2025 · Dec 31, 2024 $11.06M
Cash And Equivalents FY 2025 · Dec 31, 2023 $22.54M
Stockholders Equity FY 2025 · Dec 31, 2025 $67.48M
Stockholders Equity FY 2025 · Dec 31, 2024 $70.02M
Current Liabilities FY 2025 · Dec 31, 2025 $15.15M
Current Liabilities FY 2025 · Dec 31, 2024 $14.97M
Current Assets FY 2025 · Dec 31, 2025 $80.24M
Current Assets FY 2025 · Dec 31, 2024 $81.95M
Total Assets FY 2025 · Dec 31, 2025 $93M
Total Assets FY 2025 · Dec 31, 2024 $96.83M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.80
Eps Diluted FY 2025 · Dec 31, 2024 −$0.86
Eps Diluted FY 2025 · Dec 31, 2023 −$0.94
Eps Basic FY 2025 · Dec 31, 2025 −$0.80
Eps Basic FY 2025 · Dec 31, 2024 −$0.86
Eps Basic FY 2025 · Dec 31, 2023 −$0.94
Sga Expense FY 2025 · Dec 31, 2025 $17.6M
Sga Expense FY 2025 · Dec 31, 2024 $13.78M
Sga Expense FY 2025 · Dec 31, 2023 $12.98M
Rd Expense FY 2025 · Dec 31, 2025 $60.22M
Rd Expense FY 2025 · Dec 31, 2024 $54.37M
Rd Expense FY 2025 · Dec 31, 2023 $42.29M
Net Income FY 2025 · Dec 31, 2025 −$74.12M
Net Income FY 2025 · Dec 31, 2024 −$64.02M
Net Income FY 2025 · Dec 31, 2023 −$50.39M
Operating Income FY 2025 · Dec 31, 2025 −$77.63M
Operating Income FY 2025 · Dec 31, 2024 −$67.91M
Operating Income FY 2025 · Dec 31, 2023 −$54.92M
Revenue FY 2025 · Dec 31, 2025 $190K
Revenue FY 2025 · Dec 31, 2024 $235K
Revenue FY 2025 · Dec 31, 2023 $353K